Literature DB >> 16938020

The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease.

Aleksandra Slabosz1, Simon J G Lewis, Kamila Smigasiewicz, Blazej Szymura, Roger A Barker, Adrian M Owen.   

Abstract

In this study, the cognitive and neurochemical factors underlying learned irrelevance, one of the mechanisms thought to be responsible for attentional set-shifting deficits in Parkinson's disease (PD), were investigated. In a visual discrimination learning task, the extent to which a target dimension was irrelevant prior to an extra-dimensional shift was varied. Twenty patients with PD and 22 healthy participants performed the task twice, with patients tested on and off L-dopa. The patients made more errors than control participants in the condition in which the target dimension was completely irrelevant prior to the extradimensional shift, but not when it was partially reinforced. Moreover, L-dopa had no effect on the patients' task performance, despite improving their working memory. These results confirm that learned irrelevance is a significant factor in accounting for attentional set-shifting deficits in patients with PD, although unlike other executive impairments in this group, the phenomenon appears to be unrelated to their central dopaminergic deficit. ((c) 2006 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938020     DOI: 10.1037/0894-4105.20.5.578

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  15 in total

1.  Reduced activity at the 5-HT(2C) receptor enhances reversal learning by decreasing the influence of previously non-rewarded associations.

Authors:  S R O Nilsson; T L Ripley; E M Somerville; P G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2012-05-29       Impact factor: 4.530

Review 2.  Rule-based category learning in patients with Parkinson's disease.

Authors:  Amanda Price; J Vincent Filoteo; W Todd Maddox
Journal:  Neuropsychologia       Date:  2009-02-02       Impact factor: 3.139

3.  Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a dynamic foraging task.

Authors:  Robb B Rutledge; Stephanie C Lazzaro; Brian Lau; Catherine E Myers; Mark A Gluck; Paul W Glimcher
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

4.  Performance of C57BL/6J and DBA/2J mice on a touchscreen-based attentional set-shifting task.

Authors:  Price E Dickson; Michele A Calton; Guy Mittleman
Journal:  Behav Brain Res       Date:  2013-12-18       Impact factor: 3.332

5.  Perseveration and choice in Parkinson's disease: the impact of progressive frontostriatal dysfunction on action decisions.

Authors:  Laura E Hughes; Ellemarije Altena; Roger A Barker; James B Rowe
Journal:  Cereb Cortex       Date:  2012-06-01       Impact factor: 5.357

6.  Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function.

Authors:  Penny A Macdonald; Oury Monchi
Journal:  Parkinsons Dis       Date:  2011-03-06

7.  Striatal Dopamine and the Interface between Motivation and Cognition.

Authors:  Esther Aarts; Mieke van Holstein; Roshan Cools
Journal:  Front Psychol       Date:  2011-07-14

8.  Targeted training of the decision rule benefits rule-guided behavior in Parkinson's disease.

Authors:  Shawn W Ell
Journal:  Cogn Affect Behav Neurosci       Date:  2013-12       Impact factor: 3.526

9.  Differential effects of Parkinson's disease and dopamine replacement on memory encoding and retrieval.

Authors:  Alex A MacDonald; Ken N Seergobin; Adrian M Owen; Ruzbeh Tamjeedi; Oury Monchi; Hooman Ganjavi; Penny A MacDonald
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

10.  Dissociable effects of 5-HT2C receptor antagonism and genetic inactivation on perseverance and learned non-reward in an egocentric spatial reversal task.

Authors:  Simon R O Nilsson; Elizabeth M Somerville; Peter G Clifton
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.